Back

Novel blood-based biomarkers for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in patients heart failure with preserved ejection fraction

31 August 2026 (09:30 - 09:40)
Organised by: Logo
Congress Presentation Part of: Improving care in cardiac amyloidosis Infiltrative Myocardial Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Hanna Gaggin

Massachusetts General Hospital, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
In vivo gene editing with YOLT-201 for transthyretin amyloid cardiomyopathy – an open-label, first-in-human clinical trial
Doctor H. Yan (Hangzhou, CN)
Abstract
Presentation thumbnail
Assessing generalizability of an AI model for cardiac amyloidosis detection in ECGs: interim results of a multi-centre, external validation study
Assistant Professor F. Ahmad (Chicago, US)
Abstract
Presentation thumbnail
Cardiac presentation and treatment response by sex in patients with transthyretin amyloidosis: pooled analysis of vutrisiran and patisiran phase 3 studies
Assistant Professor A. Zaroui (Creteil, FR)
Abstract
Presentation thumbnail
Prognostic value of CT-derived pectoralis muscle area in tafamidis-treated ATTRwt cardiomyopathy
Doctor K. Ayai (JP)
Abstract
Presentation thumbnail
Recurrence of transthyretin amyloid cardiomyopathy following heart transplantation - a long term follow-up analysis
Doctor M. Poledniczek (Vienna, AT)
Abstract

Access the full session

Session thumbnail
Improving care in cardiac amyloidosis

The Event

Event poster

ESC Congress 2026

31 August 2026 09:30 CET
You may be interested in
thumbnail
Congress Presentation
Biomarkers for monitoring patients with cardiac amyloidosis during transthyretin-stabilizer therapy
31 August 2024
thumbnail
Congress Presentation
Hypertensive heart disease vs. Transthyretin cardiac amyloidosis: what are the differential features in real life?
1 July 2021
thumbnail
Congress Presentation
Study of the prevalence of transthyretin cardiac amyloidosis in patients with heart failure hospitalization made by nursing staff: the PREVAMYL study.
1 September 2025
thumbnail
Congress Presentation
Patients with transthyretin amyloid cardiomyopathy may have preserved, mildly reduced, or reduced ejection fraction
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources